The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia
Open accessAbstract
BACKGROUND: X-linked hypophosphatemia (XLH) is the most common heritable form of rickets and osteomalacia. XLH-associated mutations in phosphate-regulating endopeptidase (PHEX) result in elevated serum FGF23, decreased renal phosphate reabsorption, and low serum concentrations of phosphate (inorganic phosphorus, Pi) and 1,25-dihydroxyvitamin D [1,25(OH)2D]. KRN23 is a human anti-FGF23 antibody developed as a potential treatment for XLH. Here, we have assessed the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of KRN23 following a single i.v. or s.c. dose of KRN23 in adults with XLH. METHODS: Thirty-eight XLH patients were randomized to receive a single dose of KRN23 (0.003-0.3 mg/kg i.v. or 0.1-1 mg/kg s.c.) or placebo. PK, PD, immunogenicity, safety, and tolerability were assessed for up to 50 days. RESULTS: KRN23 significantly increased the maximum renal tubular threshold for phosphate reabsorption (TmP/GFR), serum Pi, and 1,25(OH)2D compared with that of placebo (P<0.01). The maximum serum Pi concentration occurred later following s.c. dosing (8-15 days) compared with that seen with i.v. dosing (0.5-4 days). The effect duration was dose related and persisted longer in patients who received s.c. administration. Changes from baseline in TmP/GFR, serum Pi, and serum 1,25(OH)2D correlated with serum KRN23 concentrations. The mean t1/2 of KRN23 was 8-12 days after i.v. administration and 13-19 days after s.c. administration. Patients did not exhibit increased nephrocalcinosis or develop hypercalciuria, hypercalcemia, anti-KRN23 antibodies, or elevated serum parathyroid hormone (PTH) or creatinine. CONCLUSION: KRN23 increased TmP/GFR, serum Pi, and serum 1,25(OH)2D. The positive effect of KR23 on serum Pi and its favorable safety profile suggest utility for KRN23 in XLH patients. Trial registration. Clinicaltrials.gov NCT00830674. Funding. Kyowa Hakko Kirin Pharma, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harrison's Principles of Internal Medicine.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-499_2 · Cited by 12,514
NOMOGRAM FOR DERIVATION OF RENAL THRESHOLD PHOSPHATE CONCENTRATION
Walton, R. J., & Bijvoet, O. L. M. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92736-1 · Cited by 886
Yamazaki, Y., Okazaki, R., Shibata, M., Hasegawa, Y., Satoh, K., Tajima, T., Takeuchi, Y., Fujita, T., Nakahara, K., Yamashita, T., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021105 · Cited by 671
A clinician's guide to X-linked hypophosphatemia
Carpenter, T. O., Imel, E. A., Holm, I. A., Jan de Beur, S. M., & Insogna, K. L. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.340 · Cited by 612
Self-citationLarsson, T., Marsell, R., Schipani, E., Ohlsson, C., Ljunggren, Ö., Tenenhouse, H. S., Jüppner, H., & Jonsson, K. B. (2004) · Endocrinology · doi:10.1210/en.2003-1768 · Cited by 499
Gattineni, J., Bates, C., Twombley, K., Dwarakanath, V., Robinson, M. L., Goetz, R., Mohammadi, M., & Baum, M. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90742.2008 · Cited by 438
Shimada, T., Urakawa, I., Yamazaki, Y., Hasegawa, H., Hino, R., Yoneya, T., Takeuchi, Y., Fujita, T., Fukumoto, S., & Yamashita, T. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.12.102 · Cited by 429
How Fibroblast Growth Factor 23 Works
Liu, S., & Quarles, L. D. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007010068 · Cited by 408
Noncompartmental Analysis Based on Statistical Moment Theory
(1982) · Drugs and the Pharmaceutical Sciences · doi:10.1201/b14095-12 · Cited by 288
Therapeutic Effects of Anti-FGF23 Antibodies in Hypophosphatemic Rickets/Osteomalacia
Aono, Y., Yamazaki, Y., Yasutake, J., Kawata, T., Hasegawa, H., Urakawa, I., Fujita, T., Wada, M., Yamashita, T., Fukumoto, S., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090509 · Cited by 265
Anti-FGF23 Neutralizing Antibodies Show the Physiological Role and Structural Features of FGF23
Yamazaki, Y., Tamada, T., Kasai, N., Urakawa, I., Aono, Y., Hasegawa, H., Fujita, T., Kuroki, R., Yamashita, T., Fukumoto, S., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080417 · Cited by 195
Fibroblast Growth Factor 23: Roles in Health and Disease
Imel, E. A., & Econs, M. J. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005050573 · Cited by 110
Self-citationAono, Y., Hasegawa, H., Yamazaki, Y., Shimada, T., Fujita, T., Yamashita, T., & Fukumoto, S. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.275 · Cited by 109
Costa, T., Marie, P. J., Scriver, C. R., Cole, D. E. C., Reade, T. M., Nogrady, B., Glorieux, F. H., & DELVIN, E. E. (1981) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-52-3-463 · Cited by 90
(1824) · The Lancet · doi:10.1016/s0140-6736(02)93400-8 · Cited by 5
Cited by
Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia
Haffner, D., Emma, F., Eastwood, D. M., Biosse Duplan, M., Bacchetta, J., Schnabel, D., Wicart, P., Bockenhauer, D., Santos, F., Levtchenko, E., et al. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0152-5 · Cited by 521
Burosumab Therapy in Children with X-Linked Hypophosphatemia
Carpenter, T. O., Whyte, M. P., Imel, E. A., Boot, A. M., Högler, W., Linglart, A., Padidela, R., van’t Hoff, W., Mao, M., Chen, C.-Y., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714641 · Cited by 479
Self-citationTherapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Degirolamo, C., Sabbà, C., & Moschetta, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.9 · Cited by 424
Insogna, K. L., Briot, K., Imel, E. A., Kamenický, P., Ruppe, M. D., Portale, A. A., Weber, T., Pitukcheewanont, P., Cheong, H. I., Jan de Beur, S., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3475 · Cited by 343
Self-citationTherapeutic management of hypophosphatemic rickets from infancy to adulthood
Linglart, A., Biosse-Duplan, M., Briot, K., Chaussain, C., Esterle, L., Guillaume-Czitrom, S., Kamenicky, P., Nevoux, J., Prié, D., Rothenbuhler, A., et al. (2014) · Endocrine Connections · doi:10.1530/ec-13-0103 · Cited by 331
Metadata
- Authors
- Carpenter, T. O., Imel, E. A., Ruppe, M. D., Weber, T. J., Klausner, M. A., Wooddell, M. M., Kawakami, T., Ito, T., Zhang, X., Humphrey, J., Insogna, K. L., & Peacock, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2014-02-24
- Volume
- 124
- Issue
- 4
- Pages
- 1587-1597
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2090490099
- Cited by
- 314
- References
- 15
- FWCI
- 21.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.